FDA Drug Safety Alert: Examination of Possible Neural Tube Defect Risks Linked to HIV Treatment Dolutegravir (Juluca, Tivicay, Triumeq)

FDA Drug Safety Alert: Examination of Possible Neural Tube Defect Risks Linked to HIV Treatment Dolutegravir (Juluca, Tivicay, Triumeq)